A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer.
Phase of Trial: Phase I
Latest Information Update: 27 May 2019
Price : $35 *
At a glance
- Drugs TPI 287 (Primary)
- Indications Advanced breast cancer; Brain metastases; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 22 May 2019 Status changed from active, no longer recruiting to discontinued.
- 14 Mar 2018 Status changed from suspended to active, no longer recruiting.
- 26 Feb 2018 Planned End Date changed from 1 Oct 2019 to 1 Dec 2019.